Wednesday, 5 August 2020

CMV (Cytomegalovirus) - specific dendritic cell vaccine trial summary

Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma

"We have now observed that nearly one-third of the GBM study patient population receiving CMV-specific DC vaccines results in exceptional long-term survivors."

No comments:

Post a comment